TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 34499903

Group type: EXPERIMENTAL
Intervention: AQUIRE training (intervention)
Number of subjects: 65

Group type: COMPARATOR
Intervention: Local standard practices (control)
Number of subjects: 65
Study: 33429174

Group type: EXPERIMENTAL
Intervention: Mometasone furoate nasal spray (2 puffs of 100 µg once daily in each nostril for 3 weeks) with olfactory training
Number of subjects: 100

Group type: COMPARATOR
Intervention: Olfactory training only
Number of subjects: 100

Group type: COMPARATOR
Intervention: Both groups (Mometasone and Control)
Number of subjects: 100
Study: 35193903

Group type: EXPERIMENTAL
Intervention: Real taVNS
Number of subjects: 90

Group type: COMPARATOR
Intervention: Sham taVNS
Number of subjects: 90
Study: 33567890

Group type: EXPERIMENTAL
Intervention: Sumatriptan (4 mg intravenous infusion over 10 min)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Placebo (intravenous infusion over 10 min)
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Sumatriptan
Number of subjects: 37

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 37
Study: 33122353

Group type: EXPERIMENTAL
Intervention: Experimental agents with single-agent activity classified as active
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Inactive agents
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Agents without known single-agent activity (pooled inactive and indeterminate)
Number of subjects: 50
Study: 33845669

Group type: EXPERIMENTAL
Intervention: Resiliency Group
Number of subjects: 92

Group type: COMPARATOR
Intervention: Negative Psychosocial Effects Group
Number of subjects: 92
Study: 32267878

Group type: EXPERIMENTAL
Intervention: Remote ischemic preconditioning (RIPC)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Sham intervention
Number of subjects: 60
Study: 35637106

Group type: EXPERIMENTAL
Intervention: 200 mg caffeine capsule
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo capsule
Number of subjects: 18
Study: 33636217

Group type: EXPERIMENTAL
Intervention: numeric-calories message
Number of subjects: 3481

Group type: EXPERIMENTAL
Intervention: PACE message
Number of subjects: 3481

Group type: EXPERIMENTAL
Intervention: vague calorie message
Number of subjects: 3481

Group type: COMPARATOR
Intervention: control message
Number of subjects: 3481

Group type: EXPERIMENTAL
Intervention: All interventions
Number of subjects: 3481

Group type: COMPARATOR
Intervention: control
Number of subjects: 3481
Study: 32078486

Group type: EXPERIMENTAL
Intervention: Dual antiplatelet therapy (DAPT) with aspirin plus clopidogrel
Number of subjects: 4550

Group type: COMPARATOR
Intervention: Aspirin alone
Number of subjects: 4550
Study: 35073193

Group type: EXPERIMENTAL
Intervention: Bilateral Transcutaneous Electrical Nerve Stimulation
Number of subjects: 0
Study: 35971525

Group type: EXPERIMENTAL
Intervention: Self-efficacy intervention (normal nursing + self-efficacy intervention)
Number of subjects: 140
Study: 32352505

Group type: EXPERIMENTAL
Intervention: Concomitant treatment with 4 cycles of nivolumab and doxorubicin, vinblastine, and dacarbazine (N-AVD)
Number of subjects: 109

Group type: EXPERIMENTAL
Intervention: Sequential treatment with 4 doses of nivolumab, 2 cycles of N-AVD, and 2 cycles of AVD followed by 30-Gy involved-site radiotherapy
Number of subjects: 109

Group type: COMPARATOR
Intervention: Nivolumab monotherapy (4 doses)
Number of subjects: 109
Study: 35193902

Group type: EXPERIMENTAL
Intervention: SPEAKS intervention (weekly psychotherapy lasting nine to 12 months)
Number of subjects: 60
Study: 33570488

Group type: EXPERIMENTAL
Intervention: Dopamine agonists and clonazepam prescriptions
Number of subjects: 11466

Group type: EXPERIMENTAL
Intervention: Cumulative prescription dose of medication
Number of subjects: 11466
Study: 32703776

Group type: EXPERIMENTAL
Intervention: Noxious cold-water immersion
Number of subjects: 40

Group type: COMPARATOR
Intervention: Warm water
Number of subjects: 40

Group type: COMPARATOR
Intervention: Warm water with voluntary suppression
Number of subjects: 40

Group type: COMPARATOR
Intervention: No intervention
Number of subjects: 40
Study: 34807760

Group type: EXPERIMENTAL
Intervention: PLG0206 (0.05, 0.125, 0.25, 0.5, or 1 mg/kg)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: PLG0206 (0.05 to 1.0 mg/kg)
Number of subjects: 48
Study: 36197728

Group type: EXPERIMENTAL
Intervention: Corrective exercises plus bracing
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Only bracing
Number of subjects: 180

Group type: COMPARATOR
Intervention: Waitlist control group
Number of subjects: 180
Study: 34446057

Group type: EXPERIMENTAL
Intervention: gemcitabine plus S‐1 (GS)
Number of subjects: 100

Group type: COMPARATOR
Intervention: gemcitabine plus nab‐paclitaxel (GA)
Number of subjects: 100
Study: 32315823

Group type: EXPERIMENTAL
Intervention: Exclusion condition (received significantly fewer passes in Cyberball game)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control condition (received an equal number of passes in Cyberball game)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Both conditions (exclusion and control)
Number of subjects: 0
Study: 33270835

Group type: EXPERIMENTAL
Intervention: Internal Hexagon (IH) connection implants
Number of subjects: 49

Group type: COMPARATOR
Intervention: Internal Conical (IC) connection implants
Number of subjects: 49
Study: 36452957

Group type: EXPERIMENTAL
Intervention: Continuous wave EA
Number of subjects: 560

Group type: EXPERIMENTAL
Intervention: Continuous wave TEAS
Number of subjects: 560

Group type: EXPERIMENTAL
Intervention: Continuous wave TEAS + EA
Number of subjects: 560

Group type: EXPERIMENTAL
Intervention: Dilatational wave EA
Number of subjects: 560

Group type: EXPERIMENTAL
Intervention: Dilatational wave TEAS
Number of subjects: 560

Group type: EXPERIMENTAL
Intervention: Dilatational wave TEAS + EA
Number of subjects: 560

Group type: COMPARATOR
Intervention: Control (no EA or TEAS)
Number of subjects: 560

Group type: EXPERIMENTAL
Intervention: All interventions
Number of subjects: 560
Study: 33115821

Group type: EXPERIMENTAL
Intervention: Semaglutide
Number of subjects: 0

Group type: COMPARATOR
Intervention: GLP-1RA comparators
Number of subjects: 0
Study: 35280228

Group type: EXPERIMENTAL
Intervention: Vitamin D3 supplementation (50,000 IU)
Number of subjects: 129

Group type: COMPARATOR
Intervention: Vitamin D3 supplementation (5,000 IU)
Number of subjects: 129

Group type: EXPERIMENTAL
Intervention: Both doses of vitamin D3 supplementation
Number of subjects: 129

Group type: EXPERIMENTAL
Intervention: Lower dose (5,000 IU)
Number of subjects: 129

Group type: EXPERIMENTAL
Intervention: Higher dose (50,000 IU)
Number of subjects: 129
Study: 32649502

Group type: EXPERIMENTAL
Intervention: Prediction model based on eight variables (maternal age, body mass index, gestational age, intrapartum magnesium sulfate for seizure prophylaxis, need for cervical ripening, prior cesarean delivery, cervical dilation, and effacement)
Number of subjects: 1357

Group type: EXPERIMENTAL
Intervention: Internal validation of the prediction model
Number of subjects: 1357
Study: 35770374

Group type: EXPERIMENTAL
Intervention: Oral cannabis (0, 10 and 25 mg ∆9-THC)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Vaporized cannabis (0, 5 and 20 mg ∆9-THC)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Oral cannabis administration
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Vaporized cannabis administration
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Immunoassays for ∆9-THC-COOH
Number of subjects: 21
Study: 34661550

Group type: EXPERIMENTAL
Intervention: MiSAOS intelligent monitoring system
Number of subjects: 60

Group type: COMPARATOR
Intervention: Standard management (Control)
Number of subjects: 60
Study: 32443332

Group type: EXPERIMENTAL
Intervention: Jia Wei Liang Xue Xiao Feng San granules
Number of subjects: 72

Group type: COMPARATOR
Intervention: Acitretin Capsule
Number of subjects: 72
Study: 35331944

Group type: EXPERIMENTAL
Intervention: Early mobilisation using a Sara Combilizer®
Number of subjects: 0

Group type: COMPARATOR
Intervention: Rest (no mobilisation)
Number of subjects: 0
Study: 34647140

Group type: EXPERIMENTAL
Intervention: Sensor-augmented pump (SAP) in predictive low glucose suspend (PLGS) mode
Number of subjects: 10

Group type: COMPARATOR
Intervention: Low glucose suspend (LGS) mode
Number of subjects: 10
Study: 33907293

Group type: EXPERIMENTAL
Intervention: fus-MRGB
Number of subjects: 199

Group type: COMPARATOR
Intervention: cog-MRGB
Number of subjects: 199
Study: 33099329

Group type: COMPARATOR
Intervention: Non-surgical treatment
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Surgical treatment
Number of subjects: 110
Study: 35801865

Group type: EXPERIMENTAL
Intervention: Individually tailored interventions (physical activity, cognitive behaviour therapy for insomnia, computerized memory training, cognitive behavioural therapy for self‐esteem)
Number of subjects: 142

Group type: COMPARATOR
Intervention: Standard treatment
Number of subjects: 142

Group type: EXPERIMENTAL
Intervention: Individually tailored interventions
Number of subjects: 142
Study: 34022838

Group type: EXPERIMENTAL
Intervention: Self-help workbook intervention
Number of subjects: 200

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 200
Study: 32112197

Group type: EXPERIMENTAL
Intervention: Cold snare polypectomy (CSP) for Ip polyps
Number of subjects: 634
Study: 35619188

Group type: EXPERIMENTAL
Intervention: Exercise intervention (supervised aerobic and strength training 2 h/week, Nordic/power walking 2 h/week)
Number of subjects: 181

Group type: EXPERIMENTAL
Intervention: Exercise intervention
Number of subjects: 181

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 181
Study: 34112840

Group type: EXPERIMENTAL
Intervention: Wide bandwidth mechanical noise
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Narrow bandwidth mechanical noise
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (no mechanical noise)
Number of subjects: 0
Study: 32418881

Group type: EXPERIMENTAL
Intervention: Pelvic floor muscle training (PFMT) - 6 sets/day, commencing 5 weeks before RP
Number of subjects: 97

Group type: COMPARATOR
Intervention: Usual care PFMT - 3 sets/day
Number of subjects: 97
Study: 35909305

Group type: EXPERIMENTAL
Intervention: Lidocaine with additional adrenaline
Number of subjects: 40

Group type: COMPARATOR
Intervention: Lidocaine only
Number of subjects: 40
Study: 32756479

Group type: EXPERIMENTAL
Intervention: Ramadan intermittent fasting (RIF) for 30 days
Number of subjects: 30

Group type: COMPARATOR
Intervention: Normal daily habits (Control Group)
Number of subjects: 30
Study: 35595209

Group type: EXPERIMENTAL
Intervention: r-TEVAR
Number of subjects: 34

Group type: COMPARATOR
Intervention: standard TEVAR
Number of subjects: 34
Study: 32589342

Group type: EXPERIMENTAL
Intervention: Lottery incentives and motivational text messages
Number of subjects: 131

Group type: COMPARATOR
Intervention: Motivational text messages only
Number of subjects: 131
Study: 36152007

Group type: EXPERIMENTAL
Intervention: Tumescent local anaesthesia
Number of subjects: 782
Study: 33153314

Group type: EXPERIMENTAL
Intervention: Classroom Observation Scale (13-item scale)
Number of subjects: 304

Group type: EXPERIMENTAL
Intervention: Classroom Observation Scale (used by teachers and researchers)
Number of subjects: 304

Group type: COMPARATOR
Intervention: Classroom Observation Scale (screen-positive children)
Number of subjects: 304
Study: 32045411

Group type: EXPERIMENTAL
Intervention: Sprint training
Number of subjects: 32

Group type: COMPARATOR
Intervention: Nordic training (NHE)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Soccer training
Number of subjects: 32
Study: 34585396

Group type: EXPERIMENTAL
Intervention: Ibudilast (50 mg, twice daily; n = 20)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Placebo (n = 25)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Ibudilast (50 mg, twice daily)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study: 36056577

Group type: EXPERIMENTAL
Intervention: PSA <3 ng/mL
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Baseline PSA 0 to 0.99 ng/mL
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Baseline PSA 1.0 to 1.99 ng/mL
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Baseline PSA 2 to 2.99 ng/mL
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: PSA <1 ng/mL
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: PSA 2 to 2.99 ng/mL
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Rescreening intervals based on PSA levels
Number of subjects: 0
Study: 33908655

Group type: EXPERIMENTAL
Intervention: Reward Re-Training (RRT)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Supportive therapy
Number of subjects: 60
Study: 32105712

Group type: EXPERIMENTAL
Intervention: EUS-guided fine-needle biopsy (FNB)
Number of subjects: 229

Group type: COMPARATOR
Intervention: EUS-guided fine-needle aspiration (FNA)
Number of subjects: 229
Study: 37638240

Group type: EXPERIMENTAL
Intervention: Hemopatch
Number of subjects: 315

Group type: COMPARATOR
Intervention: Standard closure
Number of subjects: 315

Group type: EXPERIMENTAL
Intervention: Hemopatch (hand-sewn stump closure)
Number of subjects: 315

Group type: COMPARATOR
Intervention: Standard closure (hand-sewn stump closure)
Number of subjects: 315

Group type: EXPERIMENTAL
Intervention: Hemopatch (main duct closure)
Number of subjects: 315

Group type: COMPARATOR
Intervention: Standard closure (main duct closure)
Number of subjects: 315
Study: 35924546

Group type: EXPERIMENTAL
Intervention: ropeginterferon alfa-2b
Number of subjects: 0

Group type: COMPARATOR
Intervention: anagrelide
Number of subjects: 0
Study: 32753545

Group type: EXPERIMENTAL
Intervention: TIL therapy
Number of subjects: 10
Study: 36078633

Group type: EXPERIMENTAL
Intervention: Providing free eyeglasses to students in poor provinces
Number of subjects: 0

Group type: COMPARATOR
Intervention: Providing free eyeglasses to students in wealthier provinces
Number of subjects: 0
Study: 32896456

Group type: EXPERIMENTAL
Intervention: qHBsAg <8 IU/mL in training set
Number of subjects: 359

Group type: EXPERIMENTAL
Intervention: qHBsAg <8 IU/mL in validation set
Number of subjects: 359

Group type: EXPERIMENTAL
Intervention: qHBsAg cutoff of 8 IU/mL
Number of subjects: 359

Group type: EXPERIMENTAL
Intervention: qHBsAg cutoff of 200 IU/mL in training set
Number of subjects: 359

Group type: EXPERIMENTAL
Intervention: qHBsAg in validation set
Number of subjects: 359
Study: 32721845

Group type: EXPERIMENTAL
Intervention: Magnesium sulphate (20 mg/kg iv bolus before anesthesia induction followed by 20 mg/kg/h until surgery completion)
Number of subjects: 74

Group type: COMPARATOR
Intervention: Saline (control group)
Number of subjects: 74
Study: 32456554

Group type: EXPERIMENTAL
Intervention: Bioresorbable scaffolds (BRS)
Number of subjects: 0

Group type: COMPARATOR
Intervention: First-generation Absorb
Number of subjects: 0
Study: 34409931

Group type: EXPERIMENTAL
Intervention: Motivational interviewing integrated with cognitive behavioural therapy (MI-CBT)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Cognitive behavioural therapy (CBT) alone
Number of subjects: 49
Study: 33597586

Group type: EXPERIMENTAL
Intervention: Platelet-rich plasma (PRP) (10 billion platelets)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Hyaluronic acid (HA; 4 ml)
Number of subjects: 150
Study: 33226107

Group type: EXPERIMENTAL
Intervention: Restored white pita bread (WP-R)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Fortified white pita bread (WP-F)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Plain white pita bread (WP)
Number of subjects: 0
Study: 35511592

Group type: EXPERIMENTAL
Intervention: Aerobic exercise (AE, n = 10)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Nonexercise control (CTRL, n = 10)
Number of subjects: 20
Study: 33982935

Group type: EXPERIMENTAL
Intervention: Home-based exercise intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 34059848

Group type: EXPERIMENTAL
Intervention: Condoms (24%, n = 28/117)
Number of subjects: 275

Group type: EXPERIMENTAL
Intervention: Oral contraceptive pill (22%, n = 26/117)
Number of subjects: 275
Study: 32965797

Group type: EXPERIMENTAL
Intervention: Short-term water deprivation (WD)
Number of subjects: 7

Group type: COMPARATOR
Intervention: Euhydration control condition
Number of subjects: 7
Study: 33404379

Group type: EXPERIMENTAL
Intervention: Exposure to anti-vaccine comments
Number of subjects: 1010

Group type: COMPARATOR
Intervention: Mainstream news article discussing the flu vaccine
Number of subjects: 1010
Study: 33995533

Group type: EXPERIMENTAL
Intervention: Chest-to-back skin-to-skin contact (CB-SSC)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Chest-to-chest skin-to-skin contact (CC-SSC)
Number of subjects: 0
Study: 32380894

Group type: EXPERIMENTAL
Intervention: Glycopyrrolate metered dose inhaler (GP MDI) 18 μg
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Formoterol fumarate metered dose inhaler (FF MDI) 9.6 μg
Number of subjects: 23
Study: 36008598

Group type: EXPERIMENTAL
Intervention: DASH diet
Number of subjects: 367

Group type: COMPARATOR
Intervention: Control diet
Number of subjects: 367
Study: 33932031

Group type: EXPERIMENTAL
Intervention: Nelfinavir (875 mg orally twice daily)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Nelfinavir (1250 mg orally twice daily)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Nelfinavir with concurrent CRT
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Nelfinavir
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Nelfinavir and CRT
Number of subjects: 13
Study: 32057373

Group type: EXPERIMENTAL
Intervention: Bare-metal stents (BMS)
Number of subjects: 25032

Group type: EXPERIMENTAL
Intervention: First-generation drug-eluting stents (DES1)
Number of subjects: 25032

Group type: EXPERIMENTAL
Intervention: Second-generation drug-eluting stents (DES2)
Number of subjects: 25032

Group type: EXPERIMENTAL
Intervention: All stent types
Number of subjects: 25032
Study: 34915485

Group type: EXPERIMENTAL
Intervention: APF-gel application (1.23% F applied for 4 min)
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: FV application (Duraphat®, 2.26% F) for 24 h
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: FV application (Duraphat®, 2.26% F) for 4 h
Number of subjects: 68

Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 68
Study: 32217876

Group type: EXPERIMENTAL
Intervention: Neurally adjusted ventilatory assist (n = 47)
Number of subjects: 99

Group type: COMPARATOR
Intervention: Pressure support ventilation (n = 52)
Number of subjects: 99
Study: 36189647

Group type: EXPERIMENTAL
Intervention: Albuterol + Vasoactive
Number of subjects: 146

Group type: COMPARATOR
Intervention: Placebo + Vasoactive
Number of subjects: 146
Study: 32677124

Group type: EXPERIMENTAL
Intervention: Story reading
Number of subjects: 292

Group type: EXPERIMENTAL
Intervention: Video watching
Number of subjects: 292

Group type: COMPARATOR
Intervention: Control
Number of subjects: 292
Study: 32678131

Group type: EXPERIMENTAL
Intervention: Eyelid hygiene performed twice a day for 10 days from 3 days before to 1 week after cataract surgery
Number of subjects: 69

Group type: COMPARATOR
Intervention: Control group (no eyelid hygiene)
Number of subjects: 69
Study: 34964652

Group type: COMPARATOR
Intervention: Intravitreal bevacizumab (Group-1)
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Intravitreal bevacizumab combined with dexamethasone (Group-2)
Number of subjects: 67
Study: 36141578

Group type: EXPERIMENTAL
Intervention: Dia‐Empower program
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 32431251

Group type: EXPERIMENTAL
Intervention: PROPER intervention (structured and repeated multidisciplinary medication review, supported by education and continuous evaluation)
Number of subjects: 380

Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 380

Group type: EXPERIMENTAL
Intervention: PROPER intervention
Number of subjects: 380

Group type: COMPARATOR
Intervention: PROPER intervention and Usual care
Number of subjects: 380
Study: 36307616

Group type: EXPERIMENTAL
Intervention: Diode laser treatment
Number of subjects: 20

Group type: COMPARATOR
Intervention: Sclerotherapy (injections of ethanolamine oleate)
Number of subjects: 20
Study: 32852613

Group type: EXPERIMENTAL
Intervention: Emixustat hydrochloride (daily oral doses ranging from 5 to 40 mg for 84 days)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Emixustat hydrochloride
Number of subjects: 23
Study: 32678026

Group type: EXPERIMENTAL
Intervention: Trauma Medical Home (TMH) intervention
Number of subjects: 430

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 430
Study: 35399053

Group type: COMPARATOR
Intervention: 200 IU/d vitamin D3 (control dose)
Number of subjects: 688

Group type: EXPERIMENTAL
Intervention: 2000 IU/d vitamin D3
Number of subjects: 688

Group type: EXPERIMENTAL
Intervention: 4000 IU/d vitamin D3
Number of subjects: 688
Study: 33439433

Group type: EXPERIMENTAL
Intervention: Open-ended response format
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Multiple-choice response format
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Retell response format
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Narrative text genre
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Expository text genre
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Generalizability studies
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Decision studies projecting dependability
Number of subjects: 78
Study: 32871913

Group type: EXPERIMENTAL
Intervention: External lumbar drainage (ELD)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Lumbar puncture (LP)
Number of subjects: 100
Study: 35914511

Group type: EXPERIMENTAL
Intervention: Aspirin + Ticagrelor
Number of subjects: 628

Group type: EXPERIMENTAL
Intervention: Aspirin + Clopidogrel
Number of subjects: 628
Study: 33734418

Group type: EXPERIMENTAL
Intervention: BAILAMOS dance program
Number of subjects: 14

Group type: COMPARATOR
Intervention: Waitlist control group
Number of subjects: 14
Study: 33200813

Group type: EXPERIMENTAL
Intervention: Trimetazidine (35 mg b.i.d.) on top of standard medical therapy
Number of subjects: 45

Group type: COMPARATOR
Intervention: Standard pharmacotherapy
Number of subjects: 45
Study: 33617369

Group type: EXPERIMENTAL
Intervention: Standard table DAA approach under an early discharge protocol
Number of subjects: 239
Study: 36267666

Group type: EXPERIMENTAL
Intervention: Temporary spinal cord stimulation (SCS)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Pulsed radiofrequency (PRF)
Number of subjects: 44